Rhythm Biosciences Reports 56% Quarterly Rise In ColoSTAT Test Volumes
Rhythm Biosciences said quarterly ColoSTAT test volumes rose 56% from the previous quarter, while company revenue increased 64%. Its collection network expanded to more than 100 sites from 78 at the end of March, and the company completed an independent health-economic study intended to support a potential Medicare reimbursement application. The NHS laboratory in England is now able to run ColoSTAT, with patient-sample testing the next step.
Closing price · 2026-10-27: $0.065 · +0.00%